Intervention Review

You have free access to this content

Calcium channel blockers for primary Raynaud's phenomenon

  1. Holly Ennis1,
  2. Marina E Anderson2,
  3. Jack Wilkinson3,
  4. Ariane L Herrick1,*

Editorial Group: Cochrane Vascular Group

Published Online: 30 JAN 2014

Assessed as up-to-date: 8 FEB 2013

DOI: 10.1002/14651858.CD002069.pub4


How to Cite

Ennis H, Anderson ME, Wilkinson J, Herrick AL. Calcium channel blockers for primary Raynaud's phenomenon. Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD002069. DOI: 10.1002/14651858.CD002069.pub4.

Author Information

  1. 1

    University of Manchester, Manchester Academic Health Science Centre, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester, UK

  2. 2

    University of Liverpool, Institute of Ageing and Chronic Disease, Liverpool, UK

  3. 3

    University of Manchester, Manchester Academic Health Science Centre, Biostatistics, Institute of Population Health, Manchester, UK

*Ariane L Herrick, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, University of Manchester, Manchester Academic Health Science Centre, Stopford Building, Oxford Road, Manchester, M13 9PT, UK. ariane.herrick@manchester.ac.uk.

Publication History

  1. Publication Status: New
  2. Published Online: 30 JAN 2014

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Figure 3]
Figure 3. Comparison 1 Calcium channel blockers versus placebo, Outcome: 1 Number of attacks.
[Figure 4]
Figure 4. Comparison: 1 Calcium channel blockers versus placebo, Outcome: 1.5 Number of attacks - without RTS 2000 (sensitivity analysis).
[Figure 5]
Figure 5. Comparison 1: Calcium channel blockers versus placebo, Outcome: 1.2 Number of attacks - Nifedipine trials only.
[Figure 6]
Figure 6. Comparison 1: Calcium channel blockers versus placebo, Outcome: 1.3 Number of attacks - Nicardipine trials only.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Calcium channel blockers versus placebo, Outcome 1 Number of attacks - Primary.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Calcium channel blockers versus placebo, Outcome 2 Number of attacks - without Ettinger (sensitivity analysis).
[Analysis 1.3]
Analysis 1.3. Comparison 1 Calcium channel blockers versus placebo, Outcome 3 Number of attacks - without RTS 2000 (sensitivity analysis).
[Analysis 1.4]
Analysis 1.4. Comparison 1 Calcium channel blockers versus placebo, Outcome 4 Number of attacks - Nifedipine trials only.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Calcium channel blockers versus placebo, Outcome 5 Number of attacks - Nifedipine trials only (random-effects).
[Analysis 1.6]
Analysis 1.6. Comparison 1 Calcium channel blockers versus placebo, Outcome 6 Number of attacks - Nicardipine trials only.